StockData
Evolus, Inc. logo

Evolus, Inc. (EOLS) stock

EOLSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30
$6.69+0.06 (+0.90%)

Close on Nov 17, 2026Market cap $441.88MP/E –Yield –

Evolus cash

Cash and short-term investments held at the end of each period.

Evolus's cash was $45.17M at Jun 30, 2026. For fiscal 2025 it was $53.83M, down 38.1% from the year before. The highest annual figure on record is $146.26M in fiscal 2021.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$53.83M-38.1%
FY2024Dec 31, 2024$86.95M+38.4%
FY2023Dec 31, 2023$62.84M+16.5%
FY2022Dec 31, 2022$53.92M-63.1%
FY2021Dec 31, 2021$146.26M+36.0%
FY2020Dec 31, 2020$107.56M-17.1%
FY2019Dec 31, 2019$129.80M+39.3%
FY2018Dec 31, 2018$93.16M–
FY2017Dec 31, 2017$0-100.0%
FY2016Dec 31, 2016$187.00K–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$45.17M-26.8%
Q1 FY2026Mar 31, 2026$49.79M-26.7%
Q4 FY2025Dec 31, 2025$53.83M-38.1%
Q3 FY2025Sep 30, 2025$43.52M-48.8%
Q2 FY2025Jun 30, 2025$61.74M-34.1%
Q1 FY2025Mar 31, 2025$67.89M-30.0%
Q4 FY2024Dec 31, 2024$86.95M+38.4%
Q3 FY2024Sep 30, 2024$85.04M+119.8%
Q2 FY2024Jun 30, 2024$93.67M+124.6%
Q1 FY2024Mar 31, 2024$96.96M+208.2%
Q4 FY2023Dec 31, 2023$62.84M+16.5%
Q3 FY2023Sep 30, 2023$38.69M-41.0%
Q2 FY2023Jun 30, 2023$41.71M-50.6%
Q1 FY2023Mar 31, 2023$31.46M-70.5%
Q4 FY2022Dec 31, 2022$53.92M-63.1%
Q3 FY2022Sep 30, 2022$65.57M-39.2%
Q2 FY2022Jun 30, 2022$84.48M-35.9%
Q1 FY2022Mar 31, 2022$106.67M+381.1%
Q4 FY2021Dec 31, 2021$146.26M+36.0%
Q3 FY2021Sep 30, 2021$107.80M-2.1%
Q2 FY2021Jun 30, 2021$131.74M+55.4%
Q1 FY2021Mar 31, 2021$22.17M-77.7%
Q4 FY2020Dec 31, 2020$107.56M-17.1%
Q3 FY2020Sep 30, 2020$110.12M+48.8%
Q2 FY2020Jun 30, 2020$84.75M-15.2%
Q1 FY2020Mar 31, 2020$99.64M+83.3%
Q4 FY2019Dec 31, 2019$129.80M+39.3%
Q3 FY2019Sep 30, 2019$74.03M-29.6%
Q2 FY2019Jun 30, 2019$99.90M+129.2%
Q1 FY2019Mar 31, 2019$54.37M+9.7%
Q4 FY2018Dec 31, 2018$93.16M–
Q3 FY2018Sep 30, 2018$105.17M–
Q2 FY2018Jun 30, 2018$43.59M–
Q1 FY2018Mar 31, 2018$49.57M–
Q4 FY2017Dec 31, 2017$0-100.0%
Q3 FY2017Sep 30, 2017$0–
Q2 FY2017Jun 30, 2017$0–
Q1 FY2017Mar 31, 2017$0–
Q4 FY2016Dec 31, 2016$187.00K–

More Evolus figures

See a number that looks wrong?